Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2023 | Safety and efficacy of pirtobrutinib in patients with R/R B-cell malignancies

Talha Munir • 24 Apr 2023
BSH 2023
General BTK inhibitors Pirtobrutinib

In this video, Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses the safety and efficacy of pirtobrutinib in patients with relapsed/refractory (R/R) B-cell malignancies intolerant to prior covalent Bruton’s tyrosine kinase (BTK) inhibitors. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Talha Munir

1:21
MRD dynamics between arms of the FLAIR trial: comparing PB and BM MRD in patients with CLL
Talha Munir • 12 Dec 2023
1:35
55-month follow-up from GLOW: fixed-duration Ibr+Ven vs Clb+O in treatment naïve CLL
Talha Munir • 12 Dec 2023
2:17
UK NCRI FLAIR trial: ibrutinib + venetoclax with MRD-directed duration of treatment in CLL
Talha Munir • 11 Dec 2023
1:10
GALACTIC: evaluating obinutuzumab consolidation post-chemoimmunotherapy in CLL
Talha Munir • 24 Apr 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals